Oculis Holding AG Business Summary

Oculis Holding AG (OCS) operates as a clinical-stage biopharmaceutical company specializing in the development of transformative ophthalmic and neuro-ophthalmologic therapies. The company’s business model is centered on the clinical advancement and eventual commercialization of its late-stage pipeline, generating revenue through strategic licensing, milestone payments, and future product sales. Primary business segments are categorized by its three lead assets: OCS-01 for Diabetic Macular Edema (DME), Licaminlimab (OCS-02) for Dry Eye Disease (DED), and Privosegtor (OCS-05) for neuroprotection in optic neuropathies. Oculis differentiates itself through its proprietary OPTIREACH® technology, which enables non-invasive topical delivery to the posterior segment of the eye, potentially replacing invasive intravitreal injections. Direct competitors include Alcon, Alimera Sciences, EyePoint Pharmaceuticals, and Ocular Therapeutix; Oculis occupies a unique market niche as a potential first-to-market provider of topical eye drops for DME, challenging the current standard of care dominated by surgical and injectable interventions. The leadership team is led by CEO Dr. Riad Sherif, a veteran executive who previously served as President of EMEA at Alcon and Entrepreneur in Residence at the Novartis Venture Fund. The executive suite includes CFO Sylvia Cheung, formerly of Anika Therapeutics, and CTO Gudrun Bachmann, alongside Chief Legal Officer Katie Kazem, a former capital markets partner at Cooley LLP appointed in February 2026. The company was founded on the scientific innovations of Dr. Thorsteinn Loftsson and Dr. Einar Stefánsson, who pioneered the cyclodextrin-based delivery platform. Oculis is governed by a board chaired by Anthony Rosenberg, a former Novartis executive, and includes prominent industry figures such as Christina Ackermann and Lionel Carnot. Notable institutional backing comes from investors such as D.E. Shaw & Co., Gabelli & Company, and the Novartis Venture Fund, reflecting strong market confidence in the company’s registrational-stage programs.